1. Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy
- Author
-
Jessica Hicks, Luciana Schultz, S. Jadallah, Mark L. Gonzalgo, Matthew E. Neilsen, George J. Netto, Mark P. Schoenberg, Ying Bei Chen, David Sidransky, Roula Albadine, and Angelo M. DeMarzo
- Subjects
Cancer Research ,Urinary bladder ,Tissue microarray ,biology ,business.industry ,Carcinoma in situ ,medicine.medical_treatment ,Cancer ,medicine.disease ,Cystectomy ,medicine.anatomical_structure ,Transitional cell carcinoma ,Oncology ,biology.protein ,Cancer research ,Medicine ,PTEN ,business ,PI3K/AKT/mTOR pathway - Abstract
BACKGROUND: Bladder urothelial carcinoma has high rates of mortality and morbidity. Identifying novel molecular prognostic factors and targets of therapy is crucial. Mammalian target of rapamycin (mTOR) pathway plays a pivotal role in establishing cell shape, migration, and proliferation. METHODS: Tissue microarrays were constructed from 132 cystectomies (1994-2002). Immunohistochemistry was performed for Pten, c-myc, p27, phosphorylated (phos)Akt, phosS6, and 4E-BP1. Markers were evaluated for pattern, percentage, and intensity of staining. RESULTS: Mean length of follow-up was 62.6 months (range, 1-182 months). Disease progression, overall survival (OS), and disease-specific survival (DSS) rates were 42%, 60%, and 68%, respectively. Pten showed loss of expression in 35% of bladder urothelial carcinoma. All markers showed lower expression in invasive bladder urothelial carcinoma compared with benign urothelium with the exception of 4E-BP1. Pten, p27, phosAkt, phosS6, and 4E-BP1 expression correlated with pathologic stage (pathological stage; P
- Published
- 2010
- Full Text
- View/download PDF